Embattled building products group James Hardie has paused trading on the ASX after its shares tumbled more than 10% at the ...
Biotech company Neuren Pharmaceuticals reported a 24% rise in royalties from quarterly US sales of its Retts syndrome treatment Daybue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback